Stock Market Update - Thu Nov 15 09:36:42 EST 2007

Lehman Brothers upgrades Equal-weight to Overweight. Lehman upgraded AMGN to Overweight from Equal Weight and raised their tgt to $72 from $56 following new transfusion data and likely N.C.D reconsideration and ahead of detailed phase III data for denosumab in patients with cancer related bone disease. The firm says while evidence suggesting increasing transfusion burden from N.C.D limitations may not be overwhelming, they believe that C.M.S is very sensitive to transfusion issues and will open a reconsideration of the N.C.D on this new data.